| Lead Manager/ | # of | Price Range | Dollar | SCOOP | ||
| New Filings (Proposed Symbol) | Joint-Lead Managers | Shares | Low | High | Volume | Ratings |
| Aquinox Pharmaceuticals (AQXP) | Jefferies/ Cowen and Company | $57.50 | n.a. | |||
| COUPONS.com ( COUP) | Goldman Sachs/ Allen & Company/ BofA Merrill Lynch/ RBC Capital Markets | $100.00 | n.a. | |||
| JD.com (TBA) | BofA Merrill Lynch/ UBS Investment Bank | $1,500.00 | n.a. | |||
| Paylocity Holding (PCTY) | Deutsche Bank Securities/ BofA Merrill Lynch/ William Blair | $115.00 | n.a. | |||
| n.a. (not available) | ||||||
| Postponed | ||||||
| None | ||||||
| Withdrawn | ||||||
| Aptalis Holdings (APTA) | Goldman Sachs/ J.P. Morgan | $500.00 | ||||
| New Terms | ||||||
| Amedica (AMDA) | JMP Securities | 3.18 | $10.00 | $12.00 | $35.00 | n.a. |
| CBS Outdoor Americas (CBSO) | BofA Merrill Lynch/ Goldman Sachs/ J.P. Morgan/ Morgan Stanley/ Citigroup/ Deutsche Bank Securities/ Wells Fargo Securities | $100.00 | n.a. | |||
| Celladon (CLDN) | Barclays | 5.00 | $8.00 | $8.00 | $40.00 | 2-Stars |
| Eagle Pharmaceuticals (EGRX) | Piper Jaffray/ William Blair | 3.33 | $14.00 | $16.00 | $50.00 | n.a. |
| Flexion Therapeutics (FLXN) | BMO Capital Markets/ Wells Fargo Securities | 5.00 | $12.00 | $14.00 | $65.00 | n.a. |
| Fortress Transportation and Infrastructure Investors Ltd. (FTAI) | Barclays/ Deutsche Bank Securities | $100.00 | n.a. | |||
| Ladder Capital (LADR) | Deutsche Bank Securities/ Citigroup/ Wells Fargo Securities/ BofA Merrill Lynch/ J.P. Morgan | 13.25 | $16.00 | $18.00 | $225.25 | 1-Star |
| Revance Therapeutics (RVNC) | Cowen and Company/ Piper Jaffray | 5.00 | $14.00 | $16.00 | $75.00 | 2-Stars |
| Talmer Bancorp (TLMR) | Keefe, Bruyette & Woods (A Stifel Company )/ J.P.Morgan | 15.56 | $12.50 | $14.50 | $210.00 | n.a. |
| Trevena (TRVN) | Barclays/ Jefferies | 8.50 | $7.00 | $7.00 | $59.50 | 2-Stars |
| n.a. (not available) | ||||||
| IPOs Priced | Lead | Shares | Amount | Offer | Close | % |
| Week of Jan. 27, 2014 | Manager(s) | Offered | Raised | Price | 1/31/14 | Change |
| Dicerna Pharmaceuticals (DRNA) | Jefferies/ Leerink Swann/ Stifel | 6.00 | $90.00 | $15.00 | $41.12 | 174.13% |
| Ultragenyx Pharmaceutical (RARE) | J.P. Morgan/ Morgan Stanley | 5.76 | $120.97 | $21.00 | $42.25 | 101.19% |
| Malibu Boats (MBUU) | Raymond James/ Wells Fargo Securities | 7.14 | $100.00 | $14.00 | $17.75 | 26.79% |
| Cara Therapeutics (CARA) | Stifel/ Piper Jaffray | 5.00 | $55.00 | $11.00 | $12.91 | 17.36% |
| New Home Company (The) (NWHM) | Citigroup/ J.P. Morgan/ Credit Suisse | 7.81 | $85.93 | $11.00 | $12.20 | 10.91% |
| Celladon (CLDN) | Barclays | 5.00 | $40.00 | $8.00 | $8.47 | 5.88% |
| Intrawest Resorts Holdings (SNOW) | Goldman Sachs/ Deutsche Bank Securities/ BofA Merrill Lynch | 15.63 | $187.50 | $12.00 | $11.90 | -0.83% |
| North Atlantic Drilling (NADL) | Morgan Stanley | 13.51 | $125.00 | $9.25 | $9.02 | -2.49% |
| Trevena (TRVN) | Barclays/ Jefferies | 9.25 | $64.75 | $7.00 | $6.50 | -7.14% |
